Literature DB >> 16849193

Adherence to antiretroviral therapy and its impact on clinical outcome in HIV-infected patients.

N M Ferguson1, C A Donnelly, J Hooper, A C Ghani, C Fraser, L M Bartley, R A Rode, P Vernazza, D Lapins, S L Mayer, R M Anderson.   

Abstract

We analyse data on patient adherence to prescribed regimens and surrogate markers of clinical outcome for 168 human immunodeficiency virus infected patients treated with antiretroviral therapy. Data on patient adherence consisted of dose-timing measurements collected for an average of 12 months per patient via electronic monitoring of bottle opening events. We first discuss how such data can be presented to highlight suboptimal adherence patterns and between-patient differences, before introducing two novel methods by which such data can be statistically modelled. Correlations between adherence and subsequent measures of viral load and CD4+T-cell counts are then evaluated. We show that summary measures of short-term adherence, which incorporate pharmacokinetic and pharmacodynamic data on the monitored regimen, predict suboptimal trends in viral load and CD4+T-cell counts better than measures based on adherence data alone.

Entities:  

Mesh:

Year:  2005        PMID: 16849193      PMCID: PMC1578278          DOI: 10.1098/rsif.2005.0037

Source DB:  PubMed          Journal:  J R Soc Interface        ISSN: 1742-5662            Impact factor:   4.118


  41 in total

1.  Adherence and drug resistance: predictions for therapy outcome.

Authors:  L M Wahl; M A Nowak
Journal:  Proc Biol Sci       Date:  2000-04-22       Impact factor: 5.349

2.  Effect of adherence to newly initiated antiretroviral therapy on plasma viral load.

Authors:  R Gross; W B Bilker; H M Friedman; B L Strom
Journal:  AIDS       Date:  2001-11-09       Impact factor: 4.177

3.  Non-adherence to highly active antiretroviral therapy predicts progression to AIDS.

Authors:  D R Bangsberg; S Perry; E D Charlebois; R A Clark; M Roberston; A R Zolopa; A Moss
Journal:  AIDS       Date:  2001-06-15       Impact factor: 4.177

4.  Use of a stochastic model to develop understanding of the impact of different patterns of antiretroviral drug use on resistance development.

Authors:  A N Phillips; M Youle; M Johnson; C Loveday
Journal:  AIDS       Date:  2001-11-23       Impact factor: 4.177

Review 5.  Measuring adherence to antiretroviral medications in clinical trials.

Authors:  L G Miller; R D Hays
Journal:  HIV Clin Trials       Date:  2000 Jul-Aug

6.  Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors.

Authors:  H Knobel; A Guelar; A Carmona; M Espona; A González; J L López-Colomés; P Saballs; J L Gimeno; A Díez
Journal:  AIDS Patient Care STDS       Date:  2001-04       Impact factor: 5.078

7.  Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.

Authors:  D R Bangsberg; F M Hecht; E D Charlebois; A R Zolopa; M Holodniy; L Sheiner; J D Bamberger; M A Chesney; A Moss
Journal:  AIDS       Date:  2000-03-10       Impact factor: 4.177

8.  Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study.

Authors:  Gail V Matthews; Caroline A Sabin; Sundhiya Mandalia; Fiona Lampe; Andrew N Phillips; Mark R Nelson; Mark Bower; Margaret A Johnson; Brian G Gazzard
Journal:  AIDS       Date:  2002-01-04       Impact factor: 4.177

9.  Quantification of intrinsic residual viral replication in treated HIV-infected patients.

Authors:  C Fraser; N M Ferguson; R M Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-11       Impact factor: 11.205

10.  Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration.

Authors:  N Buss; P Snell; J Bock; A Hsu; K Jorga
Journal:  Br J Clin Pharmacol       Date:  2001-09       Impact factor: 4.335

View more
  11 in total

1.  Assessing the impact of adherence to anti-retroviral therapy on treatment failure and resistance evolution in HIV.

Authors:  Dominique Cadosch; Sebastian Bonhoeffer; Roger Kouyos
Journal:  J R Soc Interface       Date:  2012-03-14       Impact factor: 4.118

2.  Modeling within-host HIV-1 dynamics and the evolution of drug resistance: trade-offs between viral enzyme function and drug susceptibility.

Authors:  Libin Rong; Michael A Gilchrist; Zhilan Feng; Alan S Perelson
Journal:  J Theor Biol       Date:  2007-04-19       Impact factor: 2.691

3.  Adherence to antiretroviral HIV drugs: how many doses can you miss before resistance emerges?

Authors:  R J Smith
Journal:  Proc Biol Sci       Date:  2006-03-07       Impact factor: 5.349

4.  Basic PK/PD principles of drug effects in circular/proliferative systems for disease modelling.

Authors:  Philippe Jacqmin; Lynn McFadyen; Janet R Wade
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-03-04       Impact factor: 2.745

5.  Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial.

Authors:  Jean-Jacques Parienti; Aurélie Barrail-Tran; Xavier Duval; Georges Nembot; Diane Descamps; Marie Vigan; Bernard Vrijens; Xavière Panhard; Anne-Marie Taburet; France Mentré; Cécile Goujard
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

6.  Getting less of what you want: reductions in statistical power and increased bias when categorizing medication adherence data.

Authors:  Stephen J Tueller; Pascal R Deboeck; Richard A Van Dorn
Journal:  J Behav Med       Date:  2016-02-27

7.  Novel Approaches for Visualizing and Analyzing Dose-Timing Data from Electronic Drug Monitors, or "How the 'Broken Window' Theory Pertains to ART Adherence".

Authors:  Christopher J Gill; Mary Bachman DeSilva; Davidson H Hamer; Xu Keyi; Ira B Wilson; Lora Sabin
Journal:  AIDS Behav       Date:  2015-11

8.  Psychiatric disorders and adherence to antiretroviral therapy among a population of HIV-infected adults in Nigeria.

Authors:  Olurotimi Adejumo; Bibilola Oladeji; Onoja Akpa; Kay Malee; Olusegun Baiyewu; Adesola Ogunniyi; Scott Evans; Baiba Berzins; Babafemi Taiwo
Journal:  Int J STD AIDS       Date:  2015-09-18       Impact factor: 1.359

Review 9.  Modeling antiretroviral drug responses for HIV-1 infected patients using differential equation models.

Authors:  Yanni Xiao; Hongyu Miao; Sanyi Tang; Hulin Wu
Journal:  Adv Drug Deliv Rev       Date:  2013-04-17       Impact factor: 15.470

10.  Modelling imperfect adherence to HIV induction therapy.

Authors:  Rachelle E Miron; Robert J Smith
Journal:  BMC Infect Dis       Date:  2010-01-12       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.